Advertisement

User-Friendly Naloxone Approved for Caregivers to Treat Opioid Overdose — Physician’s First Watch

Medical News |
April 4, 2014

User-Friendly Naloxone Approved for Caregivers to Treat Opioid Overdose

By Kelly Young

The FDA has approved an opioid-overdose treatment to be given by caregivers and family members. It is the first time that naloxone has been available by prescription to lay people. Drug overdose deaths have surpassed those from auto crashes, the agency says.

The Evzio auto-injector delivers naloxone intramuscularly or subcutaneously and provides verbal instructions to caregivers who encounter someone with a suspected overdose. It comes with a training device for family members to practice with.

After administering naloxone, the caregiver should still call 911. The drug may have to be given more than once.

In other naloxone news, a proposal from New York's attorney general would require law enforcement officials to carry naloxone kits for potential overdose victims, the New York Times reported on Thursday.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement